Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA.
Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Scand Cardiovasc J. 2022 Feb;56(1):1-3. doi: 10.1080/14017431.2021.2025264. Epub 2022 Jan 8.
Recent meta-analyses investigating dual antithrombotic therapy (DAT) versus triple antithrombotic therapy (TAT) among patients who require oral anticoagulants especially with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raised the concern of stent thrombosis (ST) and myocardial infarction (MI), however, these meta-analyses did not include all randomized trials who require oral anticoagulants. We aimed to investigate the efficacy of DAT versus TAT in these patients undergoing PCI. Our data showed the risk of ST was not significantly different in DAT vs. TAT (HR [95%CI]: 1.50 [0.97-2.34], = .07; = 0%) and MI (HR [95%CI]: 1.17 [0.95-1.45], = .14; = 0%).
最近的荟萃分析研究了需要口服抗凝剂的患者（尤其是伴有心房颤动 [AF] 的患者）中双联抗栓治疗（DAT）与三联抗栓治疗（TAT）的疗效，这些分析引起了人们对支架血栓形成（ST）和心肌梗死（MI）的关注，然而，这些荟萃分析并未纳入所有需要口服抗凝剂的随机试验。我们旨在研究这些接受 PCI 的患者中 DAT 与 TAT 的疗效。我们的数据显示，DAT 与 TAT 相比 ST 的风险无显著差异（HR [95%CI]：1.50 [0.97-2.34]， = .07； = 0%）和 MI（HR [95%CI]：1.17 [0.95-1.45]， = .14； = 0%）。
Eur Heart J Cardiovasc Pharmacother. 2019-10-1
Eur Heart J Cardiovasc Pharmacother. 2021-4-9
Cardiovasc Drugs Ther. 2024-6-4
Zotero 插件